184 related articles for article (PubMed ID: 20656185)
1. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions.
Stanworth SJ; Dyer C; Choo L; Bakrania L; Copplestone A; Llewelyn C; Norfolk D; Powter G; Littlewood T; Wood EM; Murphy MF;
Transfus Med Rev; 2010 Jul; 24(3):163-71. PubMed ID: 20656185
[TBL] [Abstract][Full Text] [Related]
2. Comparison of different platelet count thresholds to guide administration of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation.
Estcourt LJ; Stanworth SJ; Doree C; Hopewell S; Trivella M; Murphy MF
Cochrane Database Syst Rev; 2015 Nov; 2015(11):CD010983. PubMed ID: 26576687
[TBL] [Abstract][Full Text] [Related]
3. Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after chemotherapy and stem cell transplantation.
Estcourt L; Stanworth S; Doree C; Hopewell S; Murphy MF; Tinmouth A; Heddle N
Cochrane Database Syst Rev; 2012 May; (5):CD004269. PubMed ID: 22592695
[TBL] [Abstract][Full Text] [Related]
4. A therapeutic-only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation.
Crighton GL; Estcourt LJ; Wood EM; Trivella M; Doree C; Stanworth S
Cochrane Database Syst Rev; 2015 Sep; 2015(9):CD010981. PubMed ID: 26422767
[TBL] [Abstract][Full Text] [Related]
5. The TREATT Trial (TRial to EvaluAte Tranexamic acid therapy in Thrombocytopenia): safety and efficacy of tranexamic acid in patients with haematological malignancies with severe thrombocytopenia: study protocol for a double-blind randomised controlled trial.
Estcourt LJ; McQuilten Z; Powter G; Dyer C; Curnow E; Wood EM; Stanworth SJ;
Trials; 2019 Oct; 20(1):592. PubMed ID: 31615553
[TBL] [Abstract][Full Text] [Related]
6. A no-prophylaxis platelet-transfusion strategy for hematologic cancers.
Stanworth SJ; Estcourt LJ; Powter G; Kahan BC; Dyer C; Choo L; Bakrania L; Llewelyn C; Littlewood T; Soutar R; Norfolk D; Copplestone A; Smith N; Kerr P; Jones G; Raj K; Westerman DA; Szer J; Jackson N; Bardy PG; Plews D; Lyons S; Bielby L; Wood EM; Murphy MF;
N Engl J Med; 2013 May; 368(19):1771-80. PubMed ID: 23656642
[TBL] [Abstract][Full Text] [Related]
7. New strategies for the optimal use of platelet transfusions.
Blajchman MA; Slichter SJ; Heddle NM; Murphy MF
Hematology Am Soc Hematol Educ Program; 2008; ():198-204. PubMed ID: 19074082
[TBL] [Abstract][Full Text] [Related]
8. Feasibility and usefulness of self-assessment of bleeding in patients with haematological malignancies, and the association between platelet count and bleeding.
Stanworth SJ; Dyer C; Casbard A; Murphy MF
Vox Sang; 2006 Jul; 91(1):63-9. PubMed ID: 16756603
[TBL] [Abstract][Full Text] [Related]
9. Prophylactic platelet transfusion for haemorrhage after chemotherapy and stem cell transplantation.
Stanworth SJ; Hyde C; Heddle N; Rebulla P; Brunskill S; Murphy MF
Cochrane Database Syst Rev; 2004 Oct; (4):CD004269. PubMed ID: 15495093
[TBL] [Abstract][Full Text] [Related]
10. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial.
Stanworth SJ; Estcourt LJ; Llewelyn CA; Murphy MF; Wood EM;
Transfusion; 2014 Oct; 54(10):2385-93. PubMed ID: 24724863
[TBL] [Abstract][Full Text] [Related]
11. Platelet transfusion prophylaxis for patients with haematological malignancies: where to now?
Stanworth SJ; Hyde C; Brunskill S; Murphy MF
Br J Haematol; 2005 Dec; 131(5):588-95. PubMed ID: 16351634
[TBL] [Abstract][Full Text] [Related]
12. Epsilon aminocaproic acid prevents bleeding in severely thrombocytopenic patients with hematological malignancies.
Antun AG; Gleason S; Arellano M; Langston AA; McLemore ML; Gaddh M; el Rassi F; Bernal-Mizrachi L; Galipeau J; Heffner LT; Winton EF; Khoury HJ
Cancer; 2013 Nov; 119(21):3784-7. PubMed ID: 23921838
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study.
Wandt H; Schaefer-Eckart K; Wendelin K; Pilz B; Wilhelm M; Thalheimer M; Mahlknecht U; Ho A; Schaich M; Kramer M; Kaufmann M; Leimer L; Schwerdtfeger R; Conradi R; Dölken G; Klenner A; Hänel M; Herbst R; Junghanss C; Ehninger G;
Lancet; 2012 Oct; 380(9850):1309-16. PubMed ID: 22877506
[TBL] [Abstract][Full Text] [Related]
14. Hypoplastic thrombocytopenia and platelet transfusion: therapeutic goals.
Karakatsanis SJ; Papadatos SS; Syrigos KN
Hosp Pract (1995); 2019 Feb; 47(1):16-23. PubMed ID: 30409035
[TBL] [Abstract][Full Text] [Related]
15. Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis.
Stanworth SJ; Hudson CL; Estcourt LJ; Johnson RJ; Wood EM;
Haematologica; 2015 Jun; 100(6):740-7. PubMed ID: 25795717
[TBL] [Abstract][Full Text] [Related]
16. Thrombocytopenia and platelet transfusions in patients with cancer.
Valent J; Schiffer CA
Cancer Treat Res; 2011; 157():251-65. PubMed ID: 21052961
[TBL] [Abstract][Full Text] [Related]
17. Exploring the components of bleeding outcomes in transfusion trials for patients with hematologic malignancy.
Balitsky AK; Liu Y; Van der Meer PF; Heddle NM; Arnold DM
Transfusion; 2021 Jan; 61(1):286-293. PubMed ID: 33047878
[TBL] [Abstract][Full Text] [Related]
18. Pathogen-reduced platelets for the prevention of bleeding.
Butler C; Doree C; Estcourt LJ; Trivella M; Hopewell S; Brunskill SJ; Stanworth S; Murphy MF
Cochrane Database Syst Rev; 2013 Mar; (3):CD009072. PubMed ID: 23543569
[TBL] [Abstract][Full Text] [Related]
19. Dose of prophylactic platelet transfusions and prevention of hemorrhage.
Slichter SJ; Kaufman RM; Assmann SF; McCullough J; Triulzi DJ; Strauss RG; Gernsheimer TB; Ness PM; Brecher ME; Josephson CD; Konkle BA; Woodson RD; Ortel TL; Hillyer CD; Skerrett DL; McCrae KR; Sloan SR; Uhl L; George JN; Aquino VM; Manno CS; McFarland JG; Hess JR; Leissinger C; Granger S
N Engl J Med; 2010 Feb; 362(7):600-13. PubMed ID: 20164484
[TBL] [Abstract][Full Text] [Related]
20. Expected individual benefit of prophylactic platelet transfusions in hemato-oncology patients based on bleeding risks.
Cornelissen LL; Caram-Deelder C; Fustolo-Gunnink SF; Groenwold RHH; Stanworth SJ; Zwaginga JJ; van der Bom JG
Transfusion; 2021 Sep; 61(9):2578-2587. PubMed ID: 34263930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
